Nine reasons why ecstasy is not quite what it used to be

Int J Drug Policy. 2018 Jan:51:36-41. doi: 10.1016/j.drugpo.2017.09.016. Epub 2017 Nov 20.

Abstract

This paper explores the recent resurgence in use of ecstasy/MDMA in Europe and highlights keys areas of continuity and divergence between the ecstasy market of the 1990s and the current MDMA market. Based on a scoping study involving a targeted multi-source data collection exercise on MDMA, it highlights nine areas that have undergone some level of change, linked with both supply and demand for the drug. Factors discussed include: innovation in production techniques; changes in precursor chemical availability; the role of online markets; competition with other stimulants and new psychoactive substances; the increased availability of high-strength MDMA; and the shift from subcultural towards more mainstream use of the drug. The paper proposes that the MDMA on Europe's contemporary market is in some respects a third generation product with a different consumer profile, with implications that responses developed at the time of the drug's earlier iteration, may be in need of a review and revamp.

Keywords: EMCDDA; Ecstasy; Europe; MDMA; Market.

MeSH terms

  • Drug and Narcotic Control* / methods
  • Drug and Narcotic Control* / trends
  • Europe / epidemiology
  • Hallucinogens / economics
  • Hallucinogens / pharmacology
  • Humans
  • N-Methyl-3,4-methylenedioxyamphetamine / economics
  • N-Methyl-3,4-methylenedioxyamphetamine / pharmacology
  • Social Marketing
  • Substance-Related Disorders* / economics
  • Substance-Related Disorders* / epidemiology
  • Substance-Related Disorders* / prevention & control

Substances

  • Hallucinogens
  • N-Methyl-3,4-methylenedioxyamphetamine